The market for tardive dyskinesia, a movement disorder affecting 500,000 patients in the United States, will go from zero approved treatments to 2 in 2017, making it an important area to watch, said Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts.
The market for tardive dyskinesia, a movement disorder affecting 500,000 patients in the United States, will go from zero approved treatments to 2 in 2017, making it an important area to watch, said Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts.
Transcript
Is there a disease or a new drug category that payers aren't paying enough attention to?
I think tardive dyskinesia is one area that maybe a lot of payers aren't thinking about right now. Right now there are 2 drugs that are pending approval for tardive dyskinesia [Editor note: the first was approved on April 11, 2017].
So this is a condition where there's abnormal, repetitive movements. And right now there's nothing approved to treat these patients. It can be caused from high doses of dopamine, blocking agents, and chronic use of these medications. And there's about 500,000 patients in the United States that have tardive dyskinesia. Right now, Xenazine is sometimes used off label. It's a 3 times daily medication. It's only approved for Huntington's disease chorea, so that's an orphan condition. Xenazine can cause depression and suicidal ideation, so there's a lot of safety concerns with it.
But there are 2 drugs that are going to be approved for tardive dyskinesia this year, which affects 500,000 patients in the US. Ingrezza will be the first one, that's once daily, and that's expected to be approved April 11. And then Austedo, it's initially going to be approved for Huntington's disease chorea [Editor's note: it was approved April 5, 2017], that orphan condition. But it is pending approval for tardive dyskinesia, as well. So that expanded indication could occur sometime in August of this year.
So we'll have 2 new drugs for tardive dyskinesia, large patient population. It will be interesting to see how much these medications cost. Right now, for Huntington's disease, Xenazine is about $150,000 per year, but you know as the population broadens significantly with these 2 new medications it will be interesting to see how they're priced. So those are important ones to watch.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
New TROPiCS-02 Data Back Sacituzumab Govitecan for Older Patients With Breast Cancer
December 9th 2023This phase 3 study investigated sacituzumab govitecan, a Trop-2–directed antibody-drug conjugate, vs treatment of physician’s choice in pretreated patients who have endocrine-resistant hormone receptor–positive/HER2-negative breast cancer, the most common form of breast cancer.
Read More
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More